Notice: This company has been marked as potentially delisted and may not be actively trading. Vermillion (VRML) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends VRML vs. ACHV, VNRX, ICCC, OCX, CDIO, BMRA, VRAX, AWH, TRIB, and TNFAShould you be buying Vermillion stock or one of its competitors? The main competitors of Vermillion include Achieve Life Sciences (ACHV), VolitionRx (VNRX), ImmuCell (ICCC), OncoCyte (OCX), Cardio Diagnostics (CDIO), Biomerica (BMRA), Virax Biolabs Group (VRAX), Aspira Women's Health (AWH), Trinity Biotech (TRIB), and TNF Pharmaceuticals (TNFA). These companies are all part of the "medical" sector. Vermillion vs. Achieve Life Sciences VolitionRx ImmuCell OncoCyte Cardio Diagnostics Biomerica Virax Biolabs Group Aspira Women's Health Trinity Biotech TNF Pharmaceuticals Achieve Life Sciences (NASDAQ:ACHV) and Vermillion (NASDAQ:VRML) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, community ranking, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings. Do insiders & institutionals have more ownership in ACHV or VRML? 33.5% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 18.1% of Vermillion shares are held by institutional investors. 2.0% of Achieve Life Sciences shares are held by company insiders. Comparatively, 4.4% of Vermillion shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, ACHV or VRML? Achieve Life Sciences has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500. Comparatively, Vermillion has a beta of 3.47, indicating that its share price is 247% more volatile than the S&P 500. Does the media refer more to ACHV or VRML? In the previous week, Achieve Life Sciences had 5 more articles in the media than Vermillion. MarketBeat recorded 5 mentions for Achieve Life Sciences and 0 mentions for Vermillion. Achieve Life Sciences' average media sentiment score of 1.15 beat Vermillion's score of 0.00 indicating that Achieve Life Sciences is being referred to more favorably in the media. Company Overall Sentiment Achieve Life Sciences Positive Vermillion Neutral Does the MarketBeat Community prefer ACHV or VRML? Achieve Life Sciences received 130 more outperform votes than Vermillion when rated by MarketBeat users. Likewise, 70.46% of users gave Achieve Life Sciences an outperform vote while only 66.67% of users gave Vermillion an outperform vote. CompanyUnderperformOutperformAchieve Life SciencesOutperform Votes33470.46% Underperform Votes14029.54% VermillionOutperform Votes20466.67% Underperform Votes10233.33% Do analysts prefer ACHV or VRML? Achieve Life Sciences currently has a consensus target price of $14.80, indicating a potential upside of 356.79%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Achieve Life Sciences is more favorable than Vermillion.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Achieve Life Sciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33Vermillion 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is ACHV or VRML more profitable? Achieve Life Sciences has a net margin of 0.00% compared to Vermillion's net margin of -307.31%. Achieve Life Sciences' return on equity of -108.30% beat Vermillion's return on equity.Company Net Margins Return on Equity Return on Assets Achieve Life SciencesN/A -108.30% -65.20% Vermillion -307.31%-155.25%-103.47% Which has preferable earnings & valuation, ACHV or VRML? Vermillion has higher revenue and earnings than Achieve Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAchieve Life SciencesN/AN/A-$29.82M-$1.13-2.87Vermillion$4.54M8.80-$15.24MN/AN/A SummaryAchieve Life Sciences beats Vermillion on 12 of the 17 factors compared between the two stocks. Get Vermillion News Delivered to You Automatically Sign up to receive the latest news and ratings for VRML and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRML vs. The Competition Export to ExcelMetricVermillionDiagnostic Substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.94M$2.25B$5.62B$9.14BDividend YieldN/A0.69%5.36%3.98%P/E Ratio-2.415.6389.6917.66Price / Sales8.8071.071,219.4081.09Price / CashN/A16.7744.3437.71Price / Book4.563.415.134.73Net Income-$15.24M$29.98M$118.85M$225.42M Vermillion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRMLVermillionN/A$0.41+0.0%N/A-92.2%$39.94M$4.54M-2.4143Gap UpACHVAchieve Life Sciences2.0182 of 5 stars$3.12+4.5%$14.80+375.1%-36.6%$107.13MN/A-2.7620Short Interest ↑News CoverageVNRXVolitionRx1.9241 of 5 stars$0.58-7.6%$3.75+549.1%-36.8%$53.53M$1.29M-1.6080Analyst ForecastNews CoverageGap UpICCCImmuCell0.3341 of 5 stars$5.24+2.5%N/A+0.7%$46.69M$17.47M-10.4870Short Interest ↑Gap UpOCXOncoCyte3.5035 of 5 stars$2.03flat$4.42+117.6%-33.1%$34.18M$709,000.000.00120Positive NewsCDIOCardio Diagnostics2.9243 of 5 stars$0.44-4.4%$2.00+355.6%-77.7%$17.75M$20,000.000.001Short Interest ↓Gap UpBMRABiomerica1.3792 of 5 stars$0.64+6.5%N/A-34.4%$11.74M$5.41M-1.8860Short Interest ↓Gap UpVRAXVirax Biolabs Group1.7911 of 5 stars$2.07-2.8%N/A+88.2%$6.89M$84,872.000.005Short Interest ↓AWHAspira Women's Health1.6346 of 5 stars$0.40-4.8%$4.40+1,000.0%-92.7%$6.67M$9.15M-0.33110Short Interest ↓Gap UpTRIBTrinity Biotech1.0858 of 5 stars$0.76-2.3%N/A-37.1%$5.89M$56.83M-0.34480Analyst ForecastShort Interest ↓News CoverageTNFATNF PharmaceuticalsN/A$1.14-4.2%N/AN/A$3.15MN/A0.006News Coverage Related Companies and Tools Related Companies Achieve Life Sciences Competitors VolitionRx Competitors ImmuCell Competitors OncoCyte Competitors Cardio Diagnostics Competitors Biomerica Competitors Virax Biolabs Group Competitors Aspira Women's Health Competitors Trinity Biotech Competitors TNF Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VRML) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredTrump’s back in the oval office. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. And he says 2025 could be...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vermillion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vermillion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
